These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 14582675)

  • 1. Therapy of alopecia areata: on the cusp and in the future.
    Price VH
    J Investig Dermatol Symp Proc; 2003 Oct; 8(2):207-11. PubMed ID: 14582675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alopecia areata: autoimmunity--the evidence is compelling.
    Kalish RS; Gilhar A
    J Investig Dermatol Symp Proc; 2003 Oct; 8(2):164-7. PubMed ID: 14582666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new biologics in psoriasis: possible treatments for alopecia areata.
    McMichael AJ
    J Investig Dermatol Symp Proc; 2003 Oct; 8(2):217-8. PubMed ID: 14582677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction.
    Gao Z; Jin YQ; Wu W
    Oncotarget; 2017 May; 8(20):33432-33443. PubMed ID: 28418931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse model.
    Nakamura M; Jo J; Tabata Y; Ishikawa O
    Am J Pathol; 2008 Mar; 172(3):650-8. PubMed ID: 18245811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alopecia areata in animal models--new insights into pathogenesis and treatment of a T cell-mediated autoimmune disorder].
    Freyschmidt-Paul P; Happle R; Hoffman R
    J Dtsch Dermatol Ges; 2004 Apr; 2(4):260-73. PubMed ID: 16285322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistological study of the development of the cellular infiltrate in the pelage follicles of the DEBR model for alopecia areata.
    Zhang JG; Oliver RF
    Br J Dermatol; 1994 Apr; 130(4):405-14. PubMed ID: 7910477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells.
    McElwee KJ; Hoffmann R; Freyschmidt-Paul P; Wenzel E; Kissling S; Sundberg JP; Zöller M
    J Invest Dermatol; 2002 Dec; 119(6):1426-33. PubMed ID: 12485450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmunity: alopecia areata.
    Hordinsky M; Ericson M
    J Investig Dermatol Symp Proc; 2004 Jan; 9(1):73-8. PubMed ID: 14870990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alopecia areata. Clinical aspects, pathogenesis and rational therapy of a T-cell-induced autoimmune disease].
    Freyschmidt-Paul P; Happle R; Hoffmann R
    Hautarzt; 2003 Aug; 54(8):713-22. PubMed ID: 12942185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
    Trüeb RM; Dias MFRG
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):68-87. PubMed ID: 28717940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice.
    Freyschmidt-Paul P; Seiter S; Zöller M; König A; Ziegler A; Sundberg JP; Happle R; Hoffmann R
    J Invest Dermatol; 2000 Oct; 115(4):653-7. PubMed ID: 10998138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on alopecia areata.
    Kos L; Conlon J
    Curr Opin Pediatr; 2009 Aug; 21(4):475-80. PubMed ID: 19502982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of intralesional interferon alfa in the treatment of alopecia areata.
    Magee KL; Hsu SM; Tucker SB
    Arch Dermatol; 1990 Jun; 126(6):760-2. PubMed ID: 2189361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus).
    Freyschmidt-Paul P; Ziegler A; McElwee KJ; Happle R; Kissling S; Sundberg JP; Hoffmann R
    Eur J Dermatol; 2001; 11(5):405-9. PubMed ID: 11525945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What's new in dermatological research?].
    Humbert P
    Ann Dermatol Venereol; 2008 Dec; 135 Suppl 7():S326-34. PubMed ID: 19264208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas-deficient C3.MRL-Tnfrsf6(lpr) mice and Fas ligand-deficient C3H/HeJ-Tnfsf6(gld) mice are relatively resistant to the induction of alopecia areata by grafting of alopecia areata-affected skin from C3H/HeJ mice.
    Freyschmidt-Paul P; McElwee KJ; Botchkarev V; Kissling S; Wenzel E; Sundberg JP; Happle R; Hoffmann R
    J Investig Dermatol Symp Proc; 2003 Jun; 8(1):104-8. PubMed ID: 12895005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathogenesis of alopecia areata in rodent models.
    McElwee KJ; Freyschmidt-Paul P; Sundberg JP; Hoffmann R
    J Investig Dermatol Symp Proc; 2003 Jun; 8(1):6-11. PubMed ID: 12894987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic and genetic characteristics of alopecia areata (part 1).
    Alzolibani AA
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(4):191-8. PubMed ID: 22367375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.